Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition |
| |
Authors: | Catherine Van Poznak |
| |
Institution: | (1) University of Michigan, Comprehensive Cancer Center, 1500 E. Medical Center Drive, C346 Med Inn Building, Ann Arbor MI, 48109-5848, USA |
| |
Abstract: | The use of adjuvant aromatase inhibitors is associated with an increased risk of osteoporosis and fractures. The oral bisphosphonate,
risedronate - dosed as the US Food and Drug Administration approved for the treatment or prevention of postmenopausal osteoporosis
- appears to mitigate bone loss associated with 2 years of adjuvant anastrozole in women with early-stage breast cancer. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|